Baker Hughes introduced its high-performance, low-dosage FATHOM XT SUBSEA525 inhibitor that helps control asphaltene deposition in deepwater wells, providing better flow assurance and reducing remediation costs by minimizing the risk of blockages in production lines and equipment. The inhibitor was designed and certified for offshore applications using a proprietary qualification protocol and a stringent laboratory evaluation method to enable full compatibility with subsea equipment and effective performance at low treatment levels. During production, crude oils can deposit asphaltenes inside pumps and pipes, creating serious production issues such as plugged flowlines and clogged equipment, resulting in the need to stop operations and perform costly remediation procedures to get production back on line at acceptable levels. Many times, these procedures offer only temporary relief. To lessen the risk of asphaltene deposition and to enhance flow, the FATHOM XT inhibitor can be applied at low treatment levels during initial production and throughout the life of the well. The low dosage rate simplifies supply logistics, reduces on-site storage, and lowers handling risk. Baker Hughes tests and qualifies all FATHOM XT chemicals for materials compatibility and reliability by use of the company’s proprietary 16-test qualification protocol. The FATHOM XT SUBSEA525 inhibitor is the first of a new line of high-performance asphaltene inhibitors.
- For additional information, visit www.bakerhughes.com.